Update from the PSMA-dRT trial: A randomized phase III trial of PSMA-PET prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer. Test results of patients ...
CLEVELAND--(BUSINESS WIRE)--Cleveland Diagnostics, Inc., a commercial-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, announced today two ...
Cleveland Diagnostics said Monday it received Food and Drug Administration approval for a test that analyzes the structure of protein biomarkers in the blood for prostate cancer signals, to aid in ...
About 1 in 8 men will be diagnosed with prostate cancer in their lifetime, but the screening process for this relatively common cancer isn’t always straightforward. Diagnosis can be a drawn-out and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results